1. Hochberg MC. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Clin Exp Rheumatol. 2001. 19:6 Suppl 25. S15–S22.
2. Bijlsma JW, Van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW. Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann N Y Acad Sci. 2002. 966:82–90.
3. Conaghan PG, Brooks P. Disease - modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D - penicillamine. Curr Opin Rheumatol. 1996. 8:176–182.
Article
4. Breedveld FC, Dijkmans BAC. Differential therapy in early and late stages of rheumatoid arthritis. Curr Opin Rheumatol. 1996. 8:226–229.
Article
5. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001. 358:903–911.
Article
6. Weinblatt ME, Kaplan H, Germain BF, Block S, Solomon SD, Gall E, et al. Methotrexate in rheumatoid arthritis; a five year prospective multicenter study. Arthritis Rheum. 1994. 37:1492–1498.
Article
7. Sharp JT, Strand V, Leung H, Hurley F, Loew-Fiedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum. 2000. 43:495–505.
Article
8. Pisetsky DS, St Clair EW. Progress in the treatment of rheumatoid arthritis. JAMA. 2001. 286:2787–2790.
Article
9. Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Rheum. 2001. 45:240–245.
Article
10. Criscione LG, St Clair EW. Tumor necrosis factor - alpha antagonists for the treatment of rheumatic diseases. Curr Opin Rheumatol. 2002. 14:204–211.
Article
11. Patel DD. B cell-ablative therapy for the treatment of autoimmune diseases. Arthritis Rheum. 2002. 46:1984–1985.
Article
12. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol. 2002. 14:220–224.
Article